Core Insights - Aligos Therapeutics has a significant Phase II pipeline, with a focus on hepatitis B treatment through its lead program, pevifoscorvir (previously known as ALG-184) [2][3] - The company is also developing a beta thyroid agonist, ALG-009, which has completed Phase IIa testing, along with preclinical results in obesity [2] - Additionally, Aligos is working on a pan-coronavirus protease inhibitor currently in a Phase II study funded by the MRC in the U.K. [3] Company Pipeline - The lead program, pevifoscorvir, targets chronic hepatitis B virus (HBV) infection, which is recognized as the largest chronic viral infection globally [2][3] - The beta thyroid agonist, ALG-009, has shown promising results in Phase IIa testing [2] - The preclinical portfolio includes an antisense oligonucleotide targeting both hepatitis B and hepatitis delta viruses [3]